LAJIN ENT (08172) has released its interim results for 2026, reporting a revenue of HK$3.632 million, marking a 69.32% increase year-over-year. The company recorded a loss attributable to shareholders of HK$13.914 million, which represents a 66.1% rise compared to the same period last year.

The company's basic loss per share stood at 3.31 HK cents for the period under review.